See more : PF Group Holdings Limited (8221.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Herantis Pharma Oyj (HRTIS.HE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Herantis Pharma Oyj, a leading company in the Biotechnology industry within the Healthcare sector.
- DPCM Capital, Inc. (XPOA) Income Statement Analysis – Financial Results
- The Drilling Company of 1972 A/S (DRLCO.CO) Income Statement Analysis – Financial Results
- Zoa Corporation (3375.T) Income Statement Analysis – Financial Results
- Onano Industrial Corp. (6405.TW) Income Statement Analysis – Financial Results
- Diverger Limited (DVR.AX) Income Statement Analysis – Financial Results
Herantis Pharma Oyj (HRTIS.HE)
About Herantis Pharma Oyj
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.29K | 1.96K | 800.00 | 0.00 | 43.91 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 927.71K | 0.00 | 1.20M | 1.22M | 27.09K | 11.27M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -927.71K | -1.05M | -1.20M | -1.22M | -1.80K | -11.27M | 0.00 | 0.00 | 43.91 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 2.70M | 5.00M | 6.20M | 5.33M | 4.93M | 2.10M | 2.33M | 2.73M | 4.90M | 3.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.74K | 2.65M | 2.85M | 2.83M | 2.33M | 1.24M | 1.02M | 942.14K | 1.33M | 1.73M | 454.41K | 382.59K | 1.43M |
| Other Expenses | -2.86M | 0.00 | 1.30M | 709.08K | 824.29K | 230.10K | 592.95K | 748.53K | 16.17M | 2.12M | 515.27K | 0.00 | 0.00 |
| Operating Expenses | -154.37K | 7.99M | 9.05M | 8.07M | 7.16M | 3.67M | 1.02M | 4.42M | 16.17M | 7.66M | 752.43K | 382.59K | 1.44M |
| Cost & Expenses | -154.37K | 7.99M | 12.46M | 8.07M | 7.16M | 4.87M | 2.24M | 4.45M | 16.17M | 7.66M | 752.43K | 423.60K | 1.47M |
| Interest Income | 677.07K | 1.02K | 309.32 | 1.30K | 617.00 | 767.65K | 2.09M | 78.20K | 205.81K | 226.95K | 34.00 | 129.62 | 443.28 |
| Interest Expense | 551.60K | 1.33M | 63.03K | 1.08M | 868.80K | 60.64K | 309.24K | 82.53K | 84.24K | 926.75K | 28.23K | 13.96K | 9.52K |
| Depreciation & Amortization | -369.00 | 15.97M | 15.97M | 927.71K | 118.94K | 1.20M | 289.94K | 1.20M | 9.42M | 1.27M | 302.52K | 41.01K | 41.34K |
| EBITDA | 831.44K | 7.98M | 6.92M | -7.14M | -6.09M | -2.92M | -637.63K | -3.14M | -6.54M | -6.34M | -449.88K | -338.55K | -1.40M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -771,057.01% | 0.00% |
| Operating Income | 154.37K | -7.99M | -9.05M | -8.07M | -7.16M | -4.87M | -2.24M | -4.42M | -16.17M | -7.66M | -752.43K | -379.69K | -1.47M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -864,752.77% | 0.00% |
| Total Other Income/Expenses | 125.47K | -1.33M | -306.25K | -1.08M | -849.36K | 690.87K | 77.19K | -4.33K | 121.57K | -699.80K | -28.20K | -13.83K | 27.55K |
| Income Before Tax | 279.84K | -9.32M | -12.77M | -9.15M | -8.00M | -4.18M | -2.16M | -4.42M | -16.04M | -8.36M | -780.63K | -393.51K | -1.45M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,244.33% | 0.00% |
| Income Tax Expense | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.63 | 0.00 | 0.00 | 0.00 | -0.49 | 0.00 | 0.00 | 443.28 |
| Net Income | 279.84K | -9.32M | -23.58M | -9.15M | -8.00M | -4.18M | -2.16M | -4.42M | -16.04M | -8.36M | -780.63K | -393.52K | -1.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,248.89% | 0.00% |
| EPS | 0.02 | -0.64 | -2.20 | -1.18 | -1.30 | -0.85 | -0.51 | -1.02 | -3.75 | -3.05 | -0.67 | -71.16 | -261.53 |
| EPS Diluted | 0.02 | -0.64 | -2.20 | -1.18 | -1.30 | -0.85 | -0.51 | -1.02 | -3.75 | -3.05 | -0.67 | -0.32 | -1.19 |
| Weighted Avg Shares Out | 17.20M | 14.65M | 10.21M | 7.77M | 6.15M | 4.92M | 4.22M | 4.33M | 4.28M | 2.74M | 1.16M | 2.83M | 5.53K |
| Weighted Avg Shares Out (Dil) | 17.20M | 14.65M | 10.21M | 7.77M | 6.15M | 4.92M | 4.22M | 4.33M | 4.28M | 2.74M | 1.16M | 2.83M | 1.22M |
Source: https://incomestatements.info
Category: Stock Reports